These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 36563966)
61. Topographic heterogeneity of substantia nigra neurons: diversity in intrinsic membrane properties and synaptic inputs. Hajós M; Greenfield SA Neuroscience; 1993 Aug; 55(4):919-34. PubMed ID: 7901802 [TBL] [Abstract][Full Text] [Related]
64. K-ATP channels in dopamine substantia nigra neurons control bursting and novelty-induced exploration. Schiemann J; Schlaudraff F; Klose V; Bingmer M; Seino S; Magill PJ; Zaghloul KA; Schneider G; Liss B; Roeper J Nat Neurosci; 2012 Sep; 15(9):1272-80. PubMed ID: 22902720 [TBL] [Abstract][Full Text] [Related]
65. Blockade of Rapid Influx of Extracellular Zn Tamano H; Morioka H; Nishio R; Takeuchi A; Takeda A Mol Neurobiol; 2019 Jun; 56(6):4539-4548. PubMed ID: 30341553 [TBL] [Abstract][Full Text] [Related]
66. Insights into Neurodegeneration in Parkinson's Disease from Single-Cell and Spatial Genomics. Kamath T; Macosko EZ Mov Disord; 2023 Apr; 38(4):518-525. PubMed ID: 36881930 [TBL] [Abstract][Full Text] [Related]
67. Function and Regulation of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons in Motor Control and Parkinson's Disease. Carmichael K; Evans RC; Lopez E; Sun L; Kumar M; Ding J; Khaliq ZM; Cai H Front Neural Circuits; 2021; 15():644776. PubMed ID: 34079441 [TBL] [Abstract][Full Text] [Related]
69. MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson's disease. Esteves M; Abreu R; Fernandes H; Serra-Almeida C; Martins PAT; Barão M; Cristóvão AC; Saraiva C; Ferreira R; Ferreira L; Bernardino L Mol Ther; 2022 Oct; 30(10):3176-3192. PubMed ID: 35689381 [TBL] [Abstract][Full Text] [Related]
70. Axonal sprouting following lesions of the rat substantia nigra. Finkelstein DI; Stanic D; Parish CL; Tomas D; Dickson K; Horne MK Neuroscience; 2000; 97(1):99-112. PubMed ID: 10877666 [TBL] [Abstract][Full Text] [Related]
71. The effect of striatal dopaminergic grafts on the neuronal activity in the substantia nigra pars reticulata and subthalamic nucleus in hemiparkinsonian rats. Gilmour TP; Piallat B; Lieu CA; Venkiteswaran K; Ramachandra R; Rao AN; Petticoffer AC; Berk MA; Subramanian T Brain; 2011 Nov; 134(Pt 11):3276-89. PubMed ID: 21911417 [TBL] [Abstract][Full Text] [Related]
72. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Mouatt-Prigent A; Karlsson JO; Agid Y; Hirsch EC Neuroscience; 1996 Aug; 73(4):979-87. PubMed ID: 8809817 [TBL] [Abstract][Full Text] [Related]
73. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata. Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169 [TBL] [Abstract][Full Text] [Related]
74. Dendritic Architecture Predicts Montero T; Gatica RI; Farassat N; Meza R; González-Cabrera C; Roeper J; Henny P Front Neural Circuits; 2021; 15():769342. PubMed ID: 34867214 [TBL] [Abstract][Full Text] [Related]
75. Noradrenergic lesion of the locus coeruleus increases apomorphine-induced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease. Wang Y; Zhang QJ; Liu J; Ali U; Gui ZH; Hui YP; Chen L; Wu ZH; Li Q Brain Res; 2010 Jan; 1310():189-99. PubMed ID: 19896932 [TBL] [Abstract][Full Text] [Related]
76. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309 [TBL] [Abstract][Full Text] [Related]
77. In vivo detection of lateral-ventral tier nigral degeneration in Parkinson's disease. Huddleston DE; Langley J; Sedlacik J; Boelmans K; Factor SA; Hu XP Hum Brain Mapp; 2017 May; 38(5):2627-2634. PubMed ID: 28240402 [TBL] [Abstract][Full Text] [Related]
78. Oxidative stress and regulated cell death in Parkinson's disease. Dionísio PA; Amaral JD; Rodrigues CMP Ageing Res Rev; 2021 May; 67():101263. PubMed ID: 33540042 [TBL] [Abstract][Full Text] [Related]
79. Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease. Struzyna LA; Browne KD; Brodnik ZD; Burrell JC; Harris JP; Chen HI; Wolf JA; Panzer KV; Lim J; Duda JE; España RA; Cullen DK J Tissue Eng Regen Med; 2018 Jul; 12(7):1702-1716. PubMed ID: 29766664 [TBL] [Abstract][Full Text] [Related]
80. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Surmeier DJ; Guzman JN; Sanchez-Padilla J; Schumacker PT Neuroscience; 2011 Dec; 198():221-31. PubMed ID: 21884755 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]